INM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INMed Pharmaceuticals Inc (INM) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading in a pre-market weak setup at 0.6501, below its pivot level of 0.705 and near support at 0.632, while the broader structure remains bearish. With no AI Stock Picker signal, no SwingMax signal, no recent positive news, no notable insider or hedge fund accumulation, and no clear financial catalyst available, the current setup does not support an immediate long-term purchase. Given the user's impatience and preference to act now, the direct answer is to avoid buying today.
The technical trend is weak and still bearish. MACD histogram is negative at -0.00711 and contracting, which shows downside momentum remains in place. RSI_6 at 39.621 is neutral-to-weak and does not indicate a strong reversal. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, confirming the longer-term trend is still down. Current pre-market price of 0.6501 is below the pivot of 0.705 and just above S1 support at 0.632, suggesting the stock is still testing lower support rather than establishing an uptrend. The near-term pattern outlook is mixed to weak, with next-week expectation slightly negative.
No recent news in the past week. Similar-pattern stock behavior suggests a possible 4.06% move over the next month, but this is not enough to outweigh the current weak trend. No AI Stock Picker signal and no SwingMax signal reduce the case for an immediate entry.
Bearish technical structure, negative MACD, weak RSI, price below pivot, no recent news catalysts, no strong hedge fund or insider buying trends, and no recent congress trading data. The broader market is also pre-market with the S&P 500 down 1.03%, which adds a weak backdrop.
Latest quarter financial data was not available due to an error, so there is no usable revenue or earnings growth readout for the most recent quarter and season. Because of that, there is no evidence here of a clear fundamental acceleration supporting a long-term buy.
No analyst rating or price target change data was provided, so the recent Wall Street view cannot be confirmed from the dataset. Based on the available information, pros do not appear to be broadly bullish, while the cons dominate: weak trend, no news catalyst, no notable insider accumulation, and no proprietary buy signal.
